上 市 公 司 医药生物 2025 年 08 月 25 日 无锡晶海 (836547) ——业绩略超预期，底部回暖逻辑明确，全年费用端负担 出清 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2025 年 08 月 22 日 | | --- | --- | | 收盘价（元） | 27.41 | | 一年内最高/最低（元） | 31.00/11.70 | | 市净率 | 3.1 | | 股息率%（分红/股价） | 0.73 | | 流通 A 股市值（百万元） | 976 | | 上证指数/深证成指 | 3,825.76/12,166.06 | 注："股息率"以最近一年已公布分红计算 | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 8.81 | | 资产负债率% | 18.49 | | 总股本/流通 A 股（百万） | 78/36 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： -50% 0% 50% 100% 150% 08-22 09-22 10-22 11-22 12-22 01-22 02- ...

8月5日，珍酒李渡(6979.HK)披露上半年业绩预告，预计实现营业收入24亿元-25.5亿元。同日，国际知名投行摩根士丹利(以下称大摩)发布研报，给予珍酒 李渡"增持"评级，引市场广泛关注。 | ANNON ALVUR (VAL 21111, V21 7 1113 | | | | | | --- | --- | --- | --- | --- | | China/Hong Kong Consumer China | | | | | | Stock Rating | | | Overweight | | | Industry View | | | | In-Line | | Price target | | | | HK$7.60 | | Up/downside to price target (%) | | | | 11 | | Shr price, close (Aug 5, 2025) | | | | HK$6.84 | | 52-Week Range | | | | HK$10.52-5.56 | | Sh out, dil, curr (mn) | | | | 3,271 | | Mkt cap, ...

Core Insights - The company's performance in 2024 was impacted by high base effects, new store ramp-up, and increased financial expenses, leading to a decline in net profit [1] - In early 2025, store performance was under pressure, but a significant recovery was observed in March [2] - The company has outlined its operational plans for 2025, focusing on expanding its restaurant and hotel businesses while enhancing product competitiveness [4] Financial Performance - In 2024, the company achieved revenue of 2.525 billion yuan, a year-on-year increase of 5.14%, but net profit dropped to 100 million yuan, down 67.09% [1] - For Q1 2025, revenue was 690 million yuan, a slight increase of 0.17%, while net profit fell to 52 million yuan, down 21.36% [2] Business Segmentation - **Restaurant Business**: In 2024, revenue from restaurant and accommodation services was 2.205 billion yuan, up 12.69%, with a gross margin of 18.26%, down 2.49 percentage points [3] - **Food Business**: Revenue reached 311 million yuan, a significant increase of 85.52%, with a gross margin of 25.62%, down 10.07 percentage points due to promotional strategies for franchisees [3] Future Plans - The company plans to open 3-5 new restaurant locations and upgrade 20 existing ones in the Yangtze River Delta region [4] - In the hotel sector, the goal is to open 3-4 new direct-operated stores and enhance the franchise business [4] - The food business aims to expand its franchise network by adding 100-150 new stores [4] Profit Forecast - The company anticipates net profits of 210 million yuan, 330 million yuan, and 450 million yuan for the years 2025, 2026, and 2027, respectively, maintaining a "recommended" rating [4]

Core Viewpoint - Pinwo Foods reported a contradictory performance for 2024, with total revenue declining by 21.98% to 876 million yuan, while net profit attributable to shareholders surged by 109.52% to 6.99 million yuan, ending a streak of seven consecutive quarters of losses [2][5]. Group 1: Financial Performance - The turnaround in profitability for Pinwo Foods was primarily driven by a strong net profit of 12.72 million yuan in the fourth quarter of 2024, although the annual non-recurring net profit was only 1.53 million yuan, indicating weak profitability in core operations [5]. - Revenue from the dairy segment, which accounts for over 75% of total revenue, fell by 24.94% in 2024, significantly contributing to the overall revenue decline [5]. Group 2: Cost Control and Margin Improvement - Cost control was crucial for the recovery of Pinwo Foods' performance, with sales expenses reduced by 51.02% to 87.40 million yuan, and supply chain management optimization led to a gross margin increase of 3.57 percentage points to 17.66% [5]. Group 3: Strategic Challenges and Market Position - The strategic transformation efforts of Pinwo Foods have not yet provided effective support, as the company has increased R&D in cheese products and launched several new items, but struggles to find breakthroughs in a highly competitive market dominated by brands like Miaokelan [5]. - Concerns about internal confidence have arisen due to the second-largest shareholder, Wu Baigeng, reducing his stake by 3%, along with the controlling shareholder's related party, Shanghai Xili, planning to reduce their holdings, leading to a significant drop in stock price and a high price-to-sales ratio of 4.43 times, indicating valuation bubble risks [5]. Group 4: Future Outlook - Looking ahead to 2025, Pinwo Foods needs to navigate the declining trends in both volume and price in the imported dairy sector, balancing cost control with market expansion and addressing the challenges of a single product structure to escape the performance slump [6].